How Peptide Concentration-Time Curves Are Constructed

Peptide concentration-time curves are constructed by collecting biological samples at predefined times after administration, measuring peptide-related concentrations with a validated bioanalytical method, pairing each concentration with its sampling time, and plotting the resulting values on a time axis. The curve provides a visual and quantitative representation of how measurable peptide concentration changes during the study period.

Concentration-time curves are a central analytical structure within Peptide Pharmacokinetics Research. Measurements such as Cmax, Tmax, area under the curve, terminal slope, and model-derived pharmacokinetic parameters are all interpreted from or fitted to concentration-time data.

Research-use notice: InStrips products are offered for research and analytical use only. They are not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or medical condition.

A concentration-time curve is not a continuous direct recording of peptide concentration. It is usually constructed from discrete samples taken at specific times, so the apparent shape of the curve depends strongly on sampling frequency, assay sensitivity, data processing, and the method used to connect or model the observed points.

What Is a Concentration-Time Curve?

A concentration-time curve is a plot showing measured concentration against time.

Typically:

• time is placed on the horizontal axis
• concentration is placed on the vertical axis
• each point represents one measured sample
• points may be connected visually
• a mathematical model may be fitted separately

The plotted line should not be mistaken for measurements at every moment between samples.

The Curve Begins With Study Design

Before any graph can be created, researchers define the sampling plan.

The protocol may specify:

• pre-administration sampling
• early post-administration sampling
• samples around the expected maximum
• later distribution and elimination samples
• the final sampling time

The schedule is selected according to the expected pharmacokinetic profile and the study objectives.

Baseline Measurement

A pre-administration sample may be plotted at or before time zero.

Baseline is particularly relevant when:

• the peptide is endogenous
• a related molecular form is naturally present
• residual concentration from earlier administration is possible
• the assay has measurable background

Baseline correction, when used, should be prespecified and scientifically justified.

Time Zero

Time zero must be defined consistently.

It may correspond to:

• start of injection
• end of a short injection
• start of an infusion
• end of an infusion
• oral administration
• application of another dosage form

Different definitions can shift apparent Tmax and other time-related measurements.

Sampling Times Become the X-Axis Values

Each biological sample is assigned an actual collection time.

Researchers may use:

• nominal scheduled times
• actual recorded times
• protocol-defined windows
• model-ready elapsed times

For quantitative pharmacokinetic analysis, actual sample times may be important when deviations from scheduled times occur.

Measured Concentrations Become the Y-Axis Values

The bioanalytical laboratory converts sample signal into a concentration using a validated analytical process.

The reported value may depend on:

• calibration standards
• quality-control samples
• sample dilution
• extraction recovery
• instrument response
• assay range

Only concentrations supported by the analytical method should be treated as quantitative values.

Calibration Curves Are Different From Pharmacokinetic Curves

A bioanalytical calibration curve links instrument or assay response to known concentrations.

A pharmacokinetic concentration-time curve links measured biological concentration to sampling time.

The two curves answer different questions:

• calibration curve: how signal relates to concentration
• pharmacokinetic curve: how concentration relates to time

Confusing the two can lead to incorrect interpretation of analytical methods.

Sample Collection

Samples may be collected as plasma, serum, whole blood, urine, or another predefined biological matrix.

The matrix affects:

• measured concentration
• sample preparation
• stability
• protein binding
• assay interference

Curves generated from different matrices should be labelled separately.

Sample Processing

After collection, biological samples may require rapid controlled processing.

Procedures can include:

• mixing with anticoagulant
• addition of stabilizers
• centrifugation
• aliquoting
• rapid freezing
• storage at a specified temperature

Changes occurring after collection can distort the concentration-time profile.

Bioanalytical Specificity

The curve is only as specific as the assay generating its concentrations.

An assay may measure:

• intact peptide
• intact peptide plus selected fragments
• immunoreactive peptide-related material
• a labeled molecular region
• total radioactivity

The y-axis label should correspond to what is actually measured.

Units of Concentration

Peptide concentrations may be expressed using units such as:

• picograms per milliliter
• nanograms per milliliter
• micrograms per milliliter
• nanomoles per liter
• picomoles per liter

Mass and molar concentration are not interchangeable without molecular-mass conversion.

Consistent Units Are Essential

All plotted concentrations should use a consistent unit unless the graph explicitly distinguishes them.

Conversion errors can arise from:

• incorrect molecular mass
• salt-form differences
• unit-prefix errors
• free-peptide versus total-salt calculations

The molecular form used for conversion should be identified.

Linear Concentration Axes

A linear y-axis places equal concentration differences at equal visual distances.

This can make it easier to see:

• peak concentration
• absolute concentration changes
• early rising patterns
• comparisons between similar profiles

Low later concentrations may appear compressed near the axis.

Semilogarithmic Plots

Pharmacokinetic data are often displayed with a logarithmic concentration axis.

A semilog plot can make it easier to examine:

• several orders of magnitude of concentration
• later decline phases
• terminal slopes
• deviations from simple exponential behavior

Zero and negative concentration values cannot be plotted directly on a logarithmic axis.

Linear and Log Plots Can Show Different Features

The same dataset can appear very different depending on axis scaling.

A linear plot may emphasize:

• peak shape
• high concentrations

A semilog plot may emphasize:

• late concentrations
• terminal decline
• multiphasic behavior

Neither representation changes the underlying data.

Connecting Observed Points

For visualization, observed concentration points may be connected by straight lines.

This does not mean that concentration changed linearly between every sample.

The connecting line is primarily:

• a visual aid
• a way to show sequence over time
• not an additional measurement

Model-fitted curves should be identified separately from point-to-point connections.

Individual Concentration-Time Curves

A study may plot a separate curve for each participant or experimental subject.

Individual curves reveal:

• variation in peak timing
• variation in peak concentration
• differences in late decline
• unusual profiles
• multiple peaks

These patterns can be hidden by group averaging.

Mean Concentration-Time Curves

Researchers may calculate a mean concentration at each nominal sampling time and plot the resulting group profile.

Mean curves summarize central tendency but can obscure:

• different Tmax values
• different curve shapes
• multiple individual peaks
• large between-subject variability

Individual pharmacokinetic parameters are often calculated before group summary.

Median Concentration-Time Curves

Median concentrations may be used when distributions are strongly skewed or contain extreme values.

The median:

• is less influenced by extreme observations
• does not represent one actual participant’s curve
• may differ from arithmetic and geometric means

The selected summary statistic should be stated.

Geometric Mean Concentrations

Geometric means may be used for positive data with multiplicative variability.

Geometric summaries are common in pharmacokinetic comparisons because many exposure measurements are analyzed after logarithmic transformation.

The geometric mean should not be used interchangeably with the arithmetic mean without explanation.

Variability Around the Curve

Group plots may display variability using:

• standard deviation
• standard error
• confidence intervals
• percentiles
• geometric coefficient of variation

The plot should identify which variability measure is shown.

Early Sampling Defines the Rising Phase

The earliest post-administration samples determine how much of the initial concentration rise can be observed.

If sampling starts too late:

• the first measured concentration may already be near the maximum
• Tmax may be poorly characterized
• Cmax may be underestimated
• early partial AUC may be inaccurate

Sampling design is therefore part of curve construction rather than a separate issue.

Sampling Around the Peak

Samples should be sufficiently frequent around the expected maximum when peak characterization is an objective.

Researchers may use prior data from:

• pilot studies
• earlier formulations
• animal research
• modelling
• related products

The peak may still occur at a different time in individual participants.

Late Sampling

Later samples help characterize the decline after the main concentration maximum.

They can contribute to estimation of:

• AUC to the last quantifiable concentration
• terminal slope
• apparent half-life
• AUC extrapolated beyond the last sample

Sampling duration should be sufficient for the intended calculations.

Below-Quantification Values

Late or early concentrations may fall below the lower limit of quantification.

Possible analysis rules include:

• treating selected values as zero
• marking them as missing
• retaining them as below quantification
• using specialized modelling approaches

The rule should be predefined because different approaches can change summary curves and model estimates.

Missing Samples

A sample may be missing because of:

• collection failure
• insufficient volume
• processing problems
• analytical failure
• protocol deviation

Missing values should not be replaced casually by interpolated concentrations in the observed dataset.

Actual Versus Nominal Sampling Times

The planned time might be 1 hour, while the actual sample could be collected at 1.08 hours.

For some analyses:

• nominal times may be used for descriptive group plots
• actual times may be used for individual pharmacokinetic calculations
• population models may use precise elapsed times

The analytical plan should specify the approach.

Observed Cmax

Cmax is usually taken directly from the observed concentrations rather than estimated by drawing a smoother curve through the points.

If measured concentrations are:

• 2 ng/mL
• 6 ng/mL
• 9 ng/mL
• 7 ng/mL

then 9 ng/mL is the observed Cmax for that profile.

The true unobserved maximum could have occurred between samples.

Observed Tmax

Tmax is the time associated with the observed Cmax.

If the maximum measured concentration occurs at the two-hour sample, the observed Tmax is two hours under that sampling schedule.

Tmax precision is therefore limited by sample timing.

What the Absorption Phase Looks Like

For many extravascular profiles, the initial portion rises as systemic input exceeds simultaneous removal from the sampled compartment.

This early region is examined in more detail in What the Absorption Phase Means in Peptide Pharmacokinetics.

The rising curve should not be interpreted as a direct trace of membrane transport alone.

Peak Region

The peak region occurs around the highest observed concentration.

The shape may be:

• sharp
• broad
• flat
• irregular
• multi-peaked

Peak shape can reflect input rate, distribution, elimination, release, sampling frequency, and variability.

Declining Phase

After the observed maximum, concentrations often decline as systemic input decreases relative to distribution and elimination.

The decline may contain more than one kinetic phase, including:

• rapid distribution-related decline
• slower elimination-related decline
• continued input from a depot

Visual inspection alone may not identify the mechanism.

Terminal Phase

The terminal phase is the later portion of the concentration-time curve that can sometimes be approximated by a log-linear decline.

Researchers may use selected late points to estimate:

• terminal rate constant
• apparent terminal half-life
• extrapolated AUC

Selection of the terminal interval should be data driven and documented.

Terminal Phase Does Not Always Equal Elimination

In some extravascular or extended-release formulations, late concentrations may be controlled by slow absorption or release.

This can produce apparent flip-flop kinetics.

The terminal slope then may not represent the intrinsic systemic elimination rate.

Area Under the Curve

AUC is derived by integrating concentration with respect to time.

Noncompartmental calculations commonly approximate area between observed samples using numerical methods.

AUC can be reported for:

• the full observed interval
• a partial interval
• time zero to the last quantifiable concentration
• time zero extrapolated to infinity

Trapezoidal Calculation

A common method approximates the area between two adjacent concentration-time points as a trapezoid.

The calculation uses:

• the earlier concentration
• the later concentration
• the time difference between them

Adding the areas across intervals provides cumulative exposure over the measured period.

Linear and Log Trapezoidal Methods

Different numerical approaches may be used depending on whether concentrations are rising or falling.

Some analyses use:

• linear trapezoidal calculation
• logarithmic trapezoidal calculation
• a linear-up/log-down approach

The selected method should remain consistent with the analysis plan.

Partial AUC

Partial AUC measures concentration-time area over a specified subset of the profile.

It may be used to compare:

• early exposure
• exposure during a defined interval
• formulations with different release patterns

The start and end times should be prespecified when used for formal comparisons.

AUC to the Last Quantifiable Concentration

AUC to the last quantifiable sample uses only the observed period for which concentrations can be quantified.

Its value depends on:

• sampling duration
• assay sensitivity
• the final measurable concentration
• sampling density

Two studies with different sampling durations may produce different observed AUC values even for similar profiles.

AUC Extrapolated to Infinity

When appropriate, researchers may estimate remaining exposure after the last sample from the terminal slope.

The extrapolated portion depends on:

• terminal concentration
• terminal rate estimate
• quality of the late data

A large extrapolated fraction can increase uncertainty in the total estimate.

Infusion Profiles

During an intravenous infusion, concentrations may rise while material continues to enter the circulation.

The profile can depend on:

• infusion rate
• infusion duration
• distribution
• clearance

The end of infusion is an important time point when interpreting the concentration maximum.

Intravenous Bolus Profiles

After a rapid intravenous administration, the earliest measurable concentration may be high because systemic input occurs almost immediately.

The profile may then show:

• rapid distribution
• subsequent slower decline
• multiple exponential phases

Very early sampling can be necessary to characterize the initial portion.

Extravascular Profiles

After oral, subcutaneous, intramuscular, or other extravascular administration, systemic appearance generally requires an absorption process.

The curve may therefore show:

• a lag
• a rising phase
• an observed maximum
• a decline

The exact shape varies substantially by formulation and route.

Subcutaneous Curves

Subcutaneous peptide profiles may be influenced by:

• injection site
• local tissue perfusion
• concentration
• injection volume
• protein binding
• self-association
• formulation excipients

A solution and a depot formulation of the same peptide can produce very different curves.

Oral Peptide Curves

Oral peptide concentration-time profiles may display substantial variability because systemic appearance depends on multiple sequential processes.

Variables may include:

• dosage-form release
• gastric emptying
• intestinal transit
• enzyme degradation
• epithelial permeability
• food conditions

The measured profile integrates all these processes.

Extended-Release Curves

A controlled or depot formulation can produce:

• delayed concentration rise
• broader peaks
• multiple peaks
• prolonged measurable concentrations
• later terminal phases

These patterns may reflect formulation-controlled input rather than changes in systemic clearance.

Multiple-Peak Profiles

More than one concentration maximum may occur.

Potential explanations include:

• multiple release phases
• variable absorption
• different absorption regions
• redistribution
• irregular sampling

The cause cannot be established from the shape alone.

Spaghetti Plots

A graph showing many individual concentration-time curves on the same axes is sometimes called a spaghetti plot.

This can reveal:

• between-subject variability
• outlying curves
• different Tmax values
• multiple peaks
• variable terminal phases

It can become difficult to read when participant numbers are large.

Model-Predicted Curves

Population or compartmental pharmacokinetic models can generate predicted concentration-time profiles.

Plots may compare:

• observed concentrations
• individual predictions
• population predictions
• prediction intervals

Predicted curves should be visually distinguished from measured data.

Residual Analysis

Residuals represent differences between observed and model-predicted concentrations.

Residual plots can help identify:

• systematic model bias
• time-dependent mismatch
• concentration-dependent error
• outlying observations

A visually smooth model curve does not by itself establish adequate model performance.

Population Curves

Population pharmacokinetic models can estimate a typical concentration-time profile together with variability.

Model output may show:

• median prediction
• prediction intervals
• covariate-specific profiles
• simulated concentration distributions

These curves are model-derived summaries rather than direct measured profiles.

Steady-State Curves

With repeated administration, concentrations may accumulate until a repeating pattern develops under a stable regimen.

A steady-state interval may include:

• post-administration rise
• peak
• decline
• trough before the next administration

Steady state refers to a repeating kinetic pattern rather than a constant concentration.

Accumulation

Accumulation occurs when peptide from earlier administrations remains measurable when additional material is administered.

The degree of accumulation depends on:

• administration interval
• systemic elimination
• absorption duration
• formulation release

Repeat-dose curves can therefore differ from single-dose curves.

Peak and Trough Measurements

In repeated-administration studies, investigators may examine:

• maximum concentration within an interval
• minimum concentration before the next administration
• AUC over the interval
• peak-to-trough fluctuation

Sampling must be timed appropriately to characterize these features.

Normalization

Curves or pharmacokinetic parameters may sometimes be normalized by administered amount or body-size variables.

Normalization should be performed only when scientifically appropriate and clearly documented.

A normalized graph is not the same as the original observed concentration profile.

Comparing Two Curves

Visual comparison can identify obvious differences in:

• peak height
• peak timing
• overall exposure
• late decline
• variability

Formal comparisons generally require prespecified pharmacokinetic parameters and statistical methods rather than visual inspection alone.

FDA Perspective on Concentration-Time Measurements

FDA bioavailability guidance identifies concentration-time measurements such as peak exposure and total exposure as central pharmacokinetic measures. The FDA Bioavailability Studies Submitted in NDAs or INDs guidance discusses Cmax, Tmax, AUC, sampling, and systemic-exposure assessment.

The appropriate design for a peptide still depends on the route, formulation, analytical method, and specific research objective.

What a Concentration-Time Curve Does Not Establish

A curve does not independently establish:

• the exact molecular absorption pathway
• which tissue produced a concentration change
• that every detected molecule is intact peptide
• complete absorption of the administered amount
• the mechanism behind multiple peaks
• the same profile under another formulation or route

Questions to Ask When Reading a Curve

Readers should identify:

• What matrix was sampled?
• What exactly did the assay measure?
• What were the sampling times?
• Were actual or nominal times plotted?
• Was the y-axis linear or logarithmic?
• Are points individual, mean, median, or model predicted?
• How were below-quantification values handled?
• Was the peak adequately sampled?
• How long did sampling continue?

Final Perspective

Peptide concentration-time curves are constructed from a sequence of discrete biological measurements collected according to a predefined sampling design.

The graph displays when measurable peptide appears, how concentrations rise, where the observed maximum occurs, and how concentrations decline during the study period. Quantitative pharmacokinetic measurements such as Cmax, Tmax, AUC, and terminal parameters are then derived from or fitted to these data.

The curve should therefore be interpreted as a structured representation of measured samples rather than as a continuous direct observation of absorption, distribution, metabolism, and elimination.